EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer

Peter Zanvit, Dewald van Dyk, Christine Fazenbaker, Kelly McGlinchey, Weichuan Luo, Jessica M Pezold, John Meekin, Chien-Ying Chang, Rosa A Carrasco, Shannon Breen, Crystal Sao-Fong Cheung, Ariel Endlich-Frazier und 17 weitere

Journal of Clinical Investigation · 15.11.2023 · 133 (22)

DOI: 10.1172/jci169655 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.11.2023. Verfasst von Peter Zanvit und 28 weiteren Autor:innen. Beteiligte Einrichtung: Early Oncology Research. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer is generally considered an immunologically "cold" tumor type that is insensitive to immunotherapy. Targeting surface antigens on tumors through cellular therapy can induce a potent antitumor immune response to "heat up" the tumor microenvironment. However, many antigens expressed on prostate tumor cells are also found on normal tissues, potentially causing on-target, off-tumor toxicities and a suboptimal therapeutic index. Our studies revealed that six-transmembrane epithelial antigen of prostate-2 (STEAP2) was a prevalent prostate cancer antigen that displayed high, homogeneous cell surface expression across all stages of disease with limited distal normal tissue expression, making it ideal for therapeutic targeting. A multifaceted lead generation approach enabled development of an armored STEAP2 chimeric antigen receptor T cell (CAR-T) therapeutic candidate, AZD0754. This CAR-T product was armored with a dominant-negative TGF-β type II receptor, bolstering its activity in the TGF-β-rich immunosuppressive environment of prostate cancer. AZD0754 demonstrated potent and specific cytotoxicity against antigen-expressing cells in vitro despite TGF-β-rich conditions. Further, AZD0754 enforced robust, dose-dependent in vivo efficacy in STEAP2-expressing cancer cell line-derived and patient-derived xenograft mouse models, and exhibited encouraging preclinical safety. Together, these data underscore the therapeutic tractability of STEAP2 in prostate cancer as well as build confidence in the specificity, potency, and tolerability of this potentially first-in-class CAR-T therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenProstatic NeoplasmsMaleHumansMiceAnimalsImmunotherapy, AdoptiveT-LymphocytesTransforming Growth Factor betaXenograft Model Antitumor AssaysCell Line, TumorTumor MicroenvironmentOxidoreductases

Stichwörter der Autor:innen

OncologyProstate cancer

Substanzen

Receptors, Chimeric AntigenTransforming Growth Factor betaSTEAP2 protein, humanOxidoreductases

Autor:innen und Institutionen

  • Early Oncology Research.
  • Biologics Engineering.
  • Discovery Sciences, Oncology R&D, and.
  • Oncology Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Clinical Pathology Patient Safety, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Computational Pathology, AstraZeneca, Munich, Germany.

Förderung

  • NCI NIH HHS
  • AstraZeneca

Zitieren

APA

Zanvit, P., van Dyk, D., Fazenbaker, C., McGlinchey, K., Luo, W., Pezold, J. M., Meekin, J., Chang, C. Y., Carrasco, R. A., Breen, S., Cheung, C. S., Endlich-Frazier, A., Clark, B., Chu, N. J., Vantellini, A., Martin, P. L., Hoover, C. E., Riley, K., Sweet, S. M., …, & Bosco, E. E. (2023). Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer. Journal of Clinical Investigation, 133(22). https://doi.org/10.1172/jci169655

Vancouver

Zanvit P, van Dyk D, Fazenbaker C, McGlinchey K, Luo W, Pezold JM, et al. Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer. Journal of Clinical Investigation. 2023;133(22). doi:10.1172/jci169655

BibTeX
@article{Zanvit2023,
  author = {Zanvit, Peter and van Dyk, Dewald and Fazenbaker, Christine and McGlinchey, Kelly and Luo, Weichuan and Pezold, Jessica M and Meekin, John and Chang, Chien-Ying and Carrasco, Rosa A and Breen, Shannon and Cheung, Crystal Sao-Fong and Endlich-Frazier, Ariel and Clark, Benjamin and Chu, Nina J and Vantellini, Alessio and Martin, Philip L and Hoover, Clare E and Riley, Kenesha and Sweet, Steve M and Chain, David and Kim, Yeoun Jin and Tu, Eric and Harder, Nathalie and Phipps, Sandrina and Damschroder, Melissa and Gilbreth, Ryan N and Cobbold, Mark and Moody, Gordon and Bosco, Emily E},
  title = {Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  volume = {133},
  number = {22},
  doi = {10.1172/jci169655}
}
Kostenlos starten →